Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus -Eluting Stent Implantation in Hypertensive Patients

• Published in: The American journal of cardiology Vol. 100; no. 11; pp. 1625 - 1629
• Main Authors: Hong, Soon Jun, MD, PhD, Shim, Wan Joo, MD, PhD, Choi, Jong Il, MD, Joo, Hyung Joon, MD, Shin, Seung Yong, MD, Park, Seong Mi, MD, PhD, Lim, Sang Yup, MD, Lim, Do-Sun, MD, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-12-2007; Elsevier; Elsevier Limited
• Subjects: Adiponectin - blood; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Arterial hypertension. Arterial hypotension; Benzimidazoles - pharmacology; Benzimidazoles - therapeutic use; Benzoates - pharmacology; Benzoates - therapeutic use; Biological and medical sciences; Biomarkers; Blood and lymphatic vessels; Cardiology. Vascular system; Cardiovascular; Cardiovascular disease; Cholesterol - blood; Cholesterol, LDL - blood; Comparative analysis; Coronary Stenosis - blood; Coronary Stenosis - drug therapy; Cytokines; Drug-Eluting Stents; Effects; Female; Humans; Hypertension - drug therapy; Immunosuppressive Agents - pharmacology; Interleukin-6 - metabolism; Male; Medical sciences; Middle Aged; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Risk factors; Single-Blind Method; Sirolimus - pharmacology; Stents; Tetrazoles - pharmacology; Tetrazoles - therapeutic use; Tumor Necrosis Factor-alpha - metabolism; Tumors; Valine - analogs & derivatives; Valine - pharmacology; Valine - therapeutic use; Valsartan; Human; Hypertension; Late; Valsartan; Loss; Biological marker; Instrumentation therapy; Cardiovascular disease; Implantation; Patient; Inflammation; Stent; Coated material; Telmisartan; Circulatory system; Cardiology; Comparative study
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2007.06.068

We compared the effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. This was a prospective, randomized, single-blinded, 8-month follow-up study that included hypertensive patients with significant coronary artery stenosis treated with telmisartan (n = 79) or valsartan (n = 80). Risk factors such as diabetes, hyperlipidemia, smoking, and obesity were similar between groups. After 8 months of follow-up, only the telmisartan group showed significant decreases in interleukin-6 and tumor necrosis factor-α. The decreases from baseline level in total cholesterol and low-density lipoprotein cholesterol concentrations were significantly greater in the telmisartan group. The increase in adiponectin concentrations from baseline measurements was significantly greater in the telmisartan group than in the valsartan group (1.9 ± 2.7 vs 0.4 ± 2.0 μg/ml, respectively, p <0.05). Moreover, late lumen loss was significantly lower in the telmisartan group than in the valsartan group (0.1 ± 0.4 vs 0.3 ± 0.5 mm, respectively, p = 0.001). Major adverse cardiac events were similar between groups. In conclusion, compared with valsartan, telmisartan was associated with a significant decrease in late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients with significant coronary narrowing.